Medicofarma Biotech SA (WSE:MDB)
Poland · Delayed Price · Currency is PLN 0.2810
+0.0120 (4.46%)
At close: Jul 4, 2025
Medicofarma Biotech Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 0.46 | 1.22 | 0.75 | 4.25 | 3.34 | 3.65 | Upgrade | |
Revenue Growth (YoY) | -65.81% | 63.14% | -82.34% | 27.45% | -8.59% | 14.63% | Upgrade |
Cost of Revenue | 1.55 | 1.48 | 0.96 | 3.73 | 2.35 | 3.23 | Upgrade |
Gross Profit | -1.09 | -0.26 | -0.21 | 0.53 | 0.99 | 0.42 | Upgrade |
Selling, General & Admin | 0.21 | 0.24 | 0.32 | 0.35 | 0.31 | 0.8 | Upgrade |
Other Operating Expenses | 0.03 | 0.51 | 0.12 | 0.01 | 0.01 | -0.05 | Upgrade |
Operating Expenses | 1.69 | 2.3 | 2.42 | 2.1 | 1.27 | 0.78 | Upgrade |
Operating Income | -2.77 | -2.55 | -2.63 | -1.58 | -0.28 | -0.36 | Upgrade |
Interest Expense | -0.24 | -0.24 | -0.17 | -0.01 | -0.01 | -0.02 | Upgrade |
Interest & Investment Income | - | - | - | - | - | 0.01 | Upgrade |
Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 | -0.23 | Upgrade |
EBT Excluding Unusual Items | -3.02 | -2.8 | -2.81 | -1.59 | -0.33 | -0.61 | Upgrade |
Impairment of Goodwill | - | 0.48 | 0.1 | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.04 | -0.06 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | - | 0.07 | 0.01 | Upgrade |
Asset Writedown | - | - | -0.94 | - | - | -0.24 | Upgrade |
Pretax Income | -3.02 | -2.32 | -3.65 | -1.59 | -0.22 | -0.9 | Upgrade |
Income Tax Expense | -0.02 | -0.02 | -0.21 | - | - | 0.02 | Upgrade |
Net Income | -3 | -2.3 | -3.44 | -1.59 | -0.22 | -0.92 | Upgrade |
Net Income to Common | -3 | -2.3 | -3.44 | -1.59 | -0.22 | -0.92 | Upgrade |
Shares Outstanding (Basic) | 68 | 68 | 68 | 68 | 68 | 7 | Upgrade |
Shares Outstanding (Diluted) | 68 | 68 | 68 | 68 | 68 | 7 | Upgrade |
Shares Change (YoY) | - | - | - | - | 901.99% | - | Upgrade |
EPS (Basic) | -0.04 | -0.03 | -0.05 | -0.02 | -0.00 | -0.14 | Upgrade |
EPS (Diluted) | -0.04 | -0.03 | -0.05 | -0.02 | -0.00 | -0.14 | Upgrade |
Free Cash Flow | -1.57 | -1.02 | -1.1 | -0.25 | -0.48 | -0.31 | Upgrade |
Free Cash Flow Per Share | -0.02 | -0.01 | -0.02 | -0.00 | -0.01 | -0.05 | Upgrade |
Gross Margin | -234.30% | -21.07% | -27.80% | 12.35% | 29.64% | 11.54% | Upgrade |
Operating Margin | -597.21% | -208.53% | -350.57% | -37.07% | -8.53% | -9.96% | Upgrade |
Profit Margin | -645.99% | -187.82% | -458.07% | -37.38% | -6.45% | -25.09% | Upgrade |
Free Cash Flow Margin | -338.20% | -83.23% | -146.38% | -5.83% | -14.48% | -8.54% | Upgrade |
EBITDA | -1.33 | -0.53 | -0.55 | 0.17 | 0.67 | -0.33 | Upgrade |
EBITDA Margin | -285.96% | -42.94% | -72.92% | 4.04% | 19.97% | -8.91% | Upgrade |
D&A For EBITDA | 1.45 | 2.03 | 2.08 | 1.75 | 0.95 | 0.04 | Upgrade |
EBIT | -2.77 | -2.55 | -2.63 | -1.58 | -0.28 | -0.36 | Upgrade |
EBIT Margin | - | -208.53% | - | -37.07% | -8.53% | -9.96% | Upgrade |
Revenue as Reported | 0.46 | 1.22 | 0.75 | 4.25 | 3.34 | 365.03 | Upgrade |
Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.